15 July 2021 → 14 January 2024
Regional and community funding: Industrial Research Fund
Medical and health sciences
- Cancer therapy
Engineering and technology
- Biomaterials engineering not elsewhere classified
excipient cancer immunotherapy
Local administration of immunotherapeutics is burdened by low bio-availability. BioBoost is a technical solution that facilitates the interaction between these compounds and the immune cells of interest. In this way, BioBoost can be commercialized as a complementary technology for companies with a pipeline of novel immunotherapeutics.